Objective: To elucidate the mechanisms of improvement/reversal of type 2 diabetes after Roux-en-Y gastric bypass (RYGB). Methods: Fourteen morbidly obese subjects, 7 with normal glucose tolerance and 7 with type 2 diabetes, were studied before and 1 month after RYGB by euglycemic hyperinsulinemic clamp (EHC), by intravenous glucose tolerance test (IVGTT) and by oral glucose tolerance test (OGTT) in 3 different sessions. Intravenous glucose tolerance test IVGTT and OGTT insulin secretion rate (ISR) and sensitivity were obtained by the minimal model. Glucose-dependent insulinotropic polypeptide (GIP) and glucagonlike peptide-1 (GLP-1) were measured. Six healthy volunteers were used as controls. Results: Total ISR largely increased in diabetic subjects only when glucose was administered orally (37.8 ± 14.9 vs 68.3 ± 22.8 nmol; P < 0.05, preoperatively vs postoperatively). The first-phase insulin secretion was restored in type 2 diabetic after the IVGTT ( 1 × 10 −9 : 104 ± 54 vs 228 ± 88; P < 0.05, preoperatively vs postoperatively; 242 ± 99 in controls). Insulin sensitivity by EHC (M × 10 2 ) was slightly but significantly improved in both normotolerant and diabetic subjects (1.46 ± 0.22 vs 1.37 ± 0.55 mmol·min −1 ·kg −1 ; P < 0.05 and 1.53 ± 0.23 vs 1.28 ± 0.62 mmol·min −1 ·kg −1 ; P < 0.05, respectively). Quantitative insulin sensitivity check index was improved in all normotolerant (0.32 ± 0.02 vs 0.30 ± 0.02; P < 0.05) and diabetic subjects (0.33 ± 0.03 vs 0.31 ± 0.02; P < 0.05). GIP and GLP-1 levels increased both at fast and after OGTT mainly in type 2 diabetic subjects. Conclusions: The large increase of ISR response to the OGTT together with the restoration of the first-phase insulin secretion in diabetic subjects might explain the reversal of type 2 diabetes after RYGB. The large incretin secretion after the oral glucose load might contribute to the increased ISR.
of glucose control is observed within days after gastric bypass before there is any substantial weight loss. [4] [5] [6] The effect of RYGB in improving/normalizing glycemic control is long-lasting, having been documented up to 16 years from the operation. 7, 8 In addition to this relevant effect on diabetes, RYGB significantly decreased overall mortality, 9, 10 with an impressive 92% reduction in diabetes-related deaths. 10 Gastrointestinal bypass is more effective than purely restrictive procedures in controlling diabetes. In fact, le Roux et al 11 demonstrated that despite a similar weight loss, gastric bypass performed better than gastric banding in terms of improvement of glucose tolerance, which became similar to that of lean subjects. Similar results were observed after a standardized meal. 12 However, poor outcomes in diabetes resolution have been described in patients with β-cell failure. 8, 13, 14 Another interesting feature accompanying RYGB is the relatively high frequency of reactive hypoglycemia, which in fact, occurs 2 to 3 hours after meals with inappropriately high insulin and Cpeptide levels. 15, 16 Fortunately, severe hypoglycemia is a rare event as shown in a recent study based on the Swedish National Registries with 5040 subjects who underwent gastric bypass, vertical banded gastroplasty, or gastric banding for obesity. 17 In fact, only 0.2% of patients who underwent gastric bypass were hospitalized for hypoglycemia in comparison with 0.04% in the general population 17 ; however, no increased risk of hypoglycemia was observed after vertical banded gastroplasty or gastric banding, meaning that hypoglycemia is a peculiar side effect of RYGB.
Relatively few studies have addressed the early changes after RYGB in the insulin secretion simultaneously with the assessment of insulin sensitivity in normotolerant and type 2 diabetic individuals by comparing different routes of glucose administration. In patients with type 2 diabetes who underwent either RYGB or dietary weight loss, Laferrère et al 18 demonstrated that glucose tolerance and incretin effect were substantially better in RYGB patients than in dieting patients who had lost the same amount of weight. However, insulin secretion was not investigated.
Kashyap et al, 19 by using the hyperglycemic clamp, showed a better improvement of the insulin sensitivity and a more robust increase in insulin secretion after RYGB than after purely restrictive bariatric procedures. On the basis of the intravenous glucose tolerance test (IVGTT) and the minimal model analysis, Lin et al 20 found that within 1 to 6 months after RYGB, glycemic control was normalized in subjects with hyperglycemia, mainly as a consequence of hepatic insulin resistance amelioration associated with an increased disposition index.
The mechanisms responsible for the improvement in glycemic control after RYGB are still unknown; therefore, it is very important to identify the characteristics of the β-cell response to glucose, in particular by comparing the oral glucose load with the intravenous glucose challenge. In fact, nutrients are diverted from the natural absorption pathway with the jump of the duodenum and part of the jejunum and it is thus likely that the oral response to glucose might differ from the intravenous administration route. It is also interesting to ascertain whether the insulin secretion is appropriate for the degree of insulin sensitivity or whether the insulin secretory response is inappropriately high, thus causing postprandial hypoglycemia.
MATERIALS AND METHODS

Study Design
Fourteen morbidly obese subjects, 7 with normal glucose tolerance and 7 with type 2 diabetes mellitus, were studied before and 1 month after bariatric surgery. The mean age of the normal glucose tolerance group (4 men/3 women) was 41.7 ± 5.1 years, the body mass index was 43.1 ± 5.3 kg·m −2 , and the fat mass was 60.6 ± 7.0 kg. The mean age for the type 2 diabetes group (4 men/3 women) was 42.5 ± 4.0, the body mass index was 42.7 ± 4.5 kg·m −2 , and the fat mass was 58.8 ± 12.3 kg. The duration of diabetes was 1 to 4 years; 3 subjects were undergoing insulin and metformin therapy and 4 subjects were undergoing sulphonylurea and metformin therapy. Glycated hemoglobin A 1c was 8.08 ± 1.22% before RYGB and 6.10 ± 0.74% after RYGB. Six healthy volunteers (3 women/3 men), aged 39 ± 7 years, with an average body mass index of 24.6 ± 1.3 kg·m −2 , and matched by age and sex, were used as the control group.
We have defined diabetes remission at 1 month as fasting plasma glucose levels of less than 126 mg·dL −1 (to convert to mmol·L −1 , multiply by 0.0555) in addition to glycated hemoglobin A 1c values less than 6.2% without the use of oral hypoglycemic or insulin.
This study was reviewed and approved by the Institutional Human Ethics Committee in accordance with national guidelines and the Helsinki Declaration, as revised in 2000. All participants provided written informed consent to participate in the study. Additional written informed consent was obtained before the surgical procedures.
Roux-en-Y Gastric Bypass
Roux-en-Y gastric bypass involves the use of a surgical stapler to create a small and vertically oriented gastric pouch with a volume usually of less than 30 mL. The upper pouch is completely divided by the gastric remnant and is anastomosed to the jejunum, 75 cm distally to the Treitz ligament, through a narrow gastrojejunal anastomosis in a Roux-en-Y fashion. Bowel continuity is restored by an entero-entero anastomosis, between the excluded biliary limb and the alimentary limb, performed at 100 cm from the gastrojejunostomy.
Body Composition
Body weight was measured to the nearest 0.1 kg with a beam scale and height to the nearest 0.5 cm with a stadiometer (Holatin; Crosswell, Wales, United Kingdom). Total body water was determined using a tritiated water dilution method. 21 Fat-free mass in kilograms was obtained by dividing the total body water by 0.732. 21 Fat mass was calculated as the difference between the body weight and fat-free mass.
Oral Glucose Tolerance Test
A standard 75-g oral glucose tolerance test (OGTT) was performed in each patient at the baseline and at 1 month postsurgery, after an overnight fasting with blood sampling at 0, 30, 60, 90, 120, and 180 minutes. Samples were placed in chilled tubes, and plasma was separated within 20 minutes and stored at −80 • C.
Intravenous Glucose Tolerance Test
An IVGTT was performed preoperatively and within 1 month postoperatively. Between 8:00 to 9:00 AM, after a 12-hours overnight fast, an intravenous catheter was placed in 1 antecubital vein and an intravenous bolus of 0.33 g of glucose per kg of body weight with a 50% water solution was injected in the contralateral antecubital vein. Blood samples were obtained at −15, −5, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 25, 30, 40 , 50, 60, 70, 80, 100, 120, 140, 160, 180, and 240 minutes relative to the start of dextrose injection. Samples were placed in chilled tubes, and plasma was separated within 20 minutes and stored at −80 • C.
Euglycemic Hyperinsulinemic Clamp
Peripheral insulin sensitivity was evaluated by the euglycemic hyperinsulinemic clamp (EHC) 22 at the baseline and within 4 weeks after surgery. After inserting a cannula in a dorsal hand vein for sampling arterialized venous blood and another in the antecubital fossa of the contralateral arm for infusions, the subjects rested in the supine position for at least 1 hour. They were placed with one hand warmed in a heated air box set at 60 • C to obtain arterialized blood samples. Insulin sensitivity, as the total insulin-mediated glucose uptake, was determined during a primed constant infusion of insulin at the rate of 6 pmol·min −1 ·kg −1 . To maintain glycemia within a normal range in diabetic subjects, rapid insulin and potassium phosphate in saline were infused overnight before the clamp. The plasma glucose concentration was clamped at fasting levels throughout the insulin infusion by means of a variable glucose infusion and blood glucose determinations every 5 minutes. Insulin sensitivity was determined during the last 40 minutes of the clamp by computing the whole-body glucose uptake (mmol·min −1 per kg of body weight) or the clearance rate (mL·min −1 per kg of body weight) during steady-state euglycemic hyperinsulinemia.
Analytical Methods
Blood samples were drawn into ethylenediamminetetraacetic acid-evacuated tubes, with the addition of 10 μL·mL −1 of blood to a dipeptidyl-peptidase-IV inhibitor (LC0014; Linco, St Charles, MO). The plasma was immediately separated by centrifugation at 4 • C and stored at −80 • C until assay. Plasma glucose was measured by the glucose oxidase method (Beckman, Fullerton, CA). Plasma insulin was assayed by microparticle enzyme immunoassay (Abbott, Pasadena, CA), with a sensitivity of 1 μU·mL −1 and an intra-assay coefficient of variation of 6.6%. C-peptide was assayed by radioimmunoassay (MYRIA; Technogenetics, Milan, Italy): minimal detectable concentration = 17 pmol·L −1 and inter-and intra-assay coefficients of variation of 3.3 to 5.7 and 4.6 to 5.3, respectively. Immunoreactive glucosedependent insulinotropic polypeptide (GIP) levels were determined using 0.1 mL of plasma in a human GIP radioimmunoassay kit (Peninsula Laboratories, Belmont, CA). Intra-assay coefficient of variation was 6% and interassay coefficient of variation was 8% and 12% for 20 and 80 pmol·L −1 standards, respectively. Total glucagon-like peptide-1 (GLP-1) was measured by radioimmunoassay (Linco Research, St Charles, MO); intra-and interassay coefficients of variation were 9% to 14% and 11% to 20%, respectively. This assay has 100% specificity for GLP-1 (7-36), GLP-1 (9-36), and GLP-1 (7-37) and does not cross-react with glucagon (0.2%), GLP-2 (<0.01%), or exendin (<0.01%).
Mathematical Model
Mathematical models have been used to estimate the insulin sensitivity, in experimental conditions other than EHC, and the parameters that characterize the first and second phases of insulin secretion. The first phase of insulin secretion depends on the release of insulin granules docked with β-cell membrane, whereas the second phase is related to the later release of insulin contained in the reserve pool. The 2 phases are well separated in healthy subjects after oral glucose administration, whereas the first phase is drastically reduced or has disappeared in type 2 diabetic subjects. 23 The OGTT and IVGTT minimal models 24 were used to compute the insulin sensitivity (S I ). The profiles of the insulin secretion rate (ISR) and the indexes of β-cell sensitivity to glucose for the IVGTT (the first-phase β-cell sensitivity, 1 , and the second-phase sensitivity, 2 ) and for the OGTT (the dynamic β-cell sensitivity, d , and the static sensitivity, s , plus the total sensitivity, ) were computed by the C-peptide minimal model as proposed by Toffolo et al 25 and Breda et al 26 The disposition index, which describes the relationship between β-cell glucose sensitivity and insulin sensitivity, was computed as × S I . In healthy individuals, changes in insulin sensitivity are accompanied by appropriate compensatory modifications in the β-cell glucose sensitivity that leave the disposition index unchanged.
The model parameters were estimated by minimization of a weighted least-squares index, using a constrained Levenberg-Marquardt minimization routine of the MATLAB library. The standard errors of the estimates of individual parameters were evaluated by the linearization method, 27 and the coefficients of variation were found to be less than 20%.
Hepatic insulin sensitivity 28 was calculated by the quantitative insulin sensitivity check index (QUICKI): 1/(log[fasting plasma insulin] + log[fasting plasma glucose]), which is an empirical method to measure insulin sensitivity and is thus a direct term of comparison with the other methods of insulin sensitivity assessment by the minimal model and the clamp. Another index is homeostatic model assessment -insulin resistance (for estimating hepatic insulin resistance): (fasting plasma insulin × fasting plasma glucose)/405. 29
Statistics
All of the data are expressed as means ± SEM unless otherwise specified. The Wilcoxon paired-sample test and analysis of variance for repeated measurements, followed by the Tukey test, were used for intra-and intergroup comparisons, respectively. Two-sided P < 0.05 was considered significant. The correlation coefficients and the relative significance between the time courses of different quantities were evaluated. A linear regression analysis between QUICKI or 1/HOMA-IR and the clamp values of insulin sensitivity was also assessed. The statistical analysis was performed by the statistical tools of MATLAB 2010.
RESULTS
None of the patients had complications during or after bariatric surgery. Three of the 7 diabetic subjects returned to normal fasting and postprandial blood glucose levels 1 week after RYGB; 2 had a remission of diabetes after 10 days; 1 subject remained diabetic but withdrew the pharmacological therapy within 2 weeks; 1 still showed an impaired fasting glucose. However, at 1 month, all the patients showed diabetes remission as defined in the "Materials and Methods" section. A significant weight loss was observed in both diabetic (from 125.2 ± 21.9 to 113.8 ± 28.1 kg; P < 0.02) and normal glucose tolerance subjects (from 131.2 ± 18.6 to 117.1 ± 20.2 kg; P < 0.02) 1 month after RYGB. However, the major effect was on fat mass reduction ( fat mass NGT = 24 ± 15%, P < 0.02; fat mass Diab = 25 ± 19%, P < 0.02).
Insulin Secretion
No significant changes in the insulin secretion indexes and of the area under the curve were observed after RYGB in the normal glucose tolerance subjects, both during the OGTT and during the IVGTT (Table 1 ). In contrast, the insulin concentration incremental area under the curve during the OGTT was largely increased in diabetic subjects (from 6.3 ± 3.5 × 10 4 to 10.6 ± 3.9 × 10 4 pmol·L −1 ·min; P < 0.05) as shown in Figure 2 . Accordingly, the area under the curve of the ISR computed by means of the C-peptide OGTT minimal model doubled only in the latter group and s and indexes were increased significantly (Table 1) . Interestingly, the cumulative insulin secretion did not increase significantly in the IVGTT in diabetic subjects, whereas 1 index was increased and the first phase of insulin secretion was restored as shown in Figure 1 .
Insulin Sensitivity
The OGTT incremental area under the curve of glucose concentration was not significantly different after RYGB in normal glucose tolerance subjects, whereas it was significantly reduced in diabetic subjects (from 841.9 ± 70.4 to 429.9 ± 86.3 mmol·L −1 ·min; P < 0.03) as depicted in Figure 2 . The insulin sensitivity measured by the OGTT minimal model was almost doubled after RYGB in both normal glucose tolerance and type 2 diabetic subjects as reported in Table 1 .
Similar but not significant increases of insulin sensitivity were also observed after the intravenous glucose challenge ( Table 1 ). Insulin sensitivity measured by the EHC was significantly increased in both normal glucose tolerance and diabetic subjects ( Table 1 ). The QUICKI index was increased after RYGB in all subjects, whereas HOMA-IR was significantly reduced. The validation of the 2 surrogate indexes of insulin sensitivity against clamp was obtained in Because of the significant improvement in the insulin sensitivity and/or the increased ISR, the disposition index increased significantly in normal glucose tolerance and diabetic subjects without reaching, however, the values observed in healthy controls (Table 1 ).
Incretin Profile
Stimulated levels of incretins increased significantly after surgery (Fig. 3) . The peak of GLP-1 concentration increased from 14.2 ± 4.0 to 28.8 ± 8.2 pmol·L −1 (normal glucose tolerance subjects) and from 17.8 ± 2.9 to 34.8 ± 10.3 (diabetic subjects); P < 0.05, and the incremental GLP-1 area under the curve from 87.3 ± 33.8 to 1146 ± 565.3 (normal glucose tolerance subjects) and from 775.8 ± 89.7 to 2085.0 ± 495.5 (diabetic subjects) pmol·L −1 ·min (P < 0.05). Similarly, the peak of GIP concentration increased from 22.6 ± 4.4 to 63.4 ± 15.6 (normal glucose tolerance subjects) and from 42.2 ± 27.9 to 94.8 ± 13.3 (diabetic subjects) pmol·L −1 ; P < 0.05, and its incremental area under the curve raised from 2548 ± 291.3 to 7356 ± 608.7 (normal glucose tolerance subjects) and from 4092 ± 952.6 to 11,049 ± 743.2 (diabetic subjects) pmol·L −1 ·min (P < 0.05). There was no significant change in the incremental area under the curve for both GLP-1 (37.2 ± 62.0 vs 24.9 ± 61.6 and 28.7 ± 59.5 vs 36.3 ± 81.5, preoperatively vs postoperatively in normal glucose tolerance and type 2 diabetes, respectively), and GIP (34.2 ± 54.5 vs 29.3 ± 48.1 and 34.9 ± 41.3 vs 18.9 ± 72.3, preoperatively vs postoperatively in normal glucose tolerance and type 2 diabetes, respectively) after the IVGTT.
It is of interest to assess whether the increase after surgery of GLP-1 concentrations related to the increase of ISR. To this aim, we computed the differences between the average GLP-1 concentration after RYGB and the average GLP-1 concentration before RYGB, say GLP-1, at all measurement times. Similarly, we computed the differences for the average ISR, say ISR at all times, and the correlation coefficient (R) of ISR versus GLP-1 was computed. The values of R were 0.96 (P < 0.001) (normal glucose tolerance subjects) and 0.86 
DISCUSSION
The major findings of our study are the following: A few days after the operation, all the diabetic subjects discontinued the antidiabetic drugs. The most interesting finding is that the ISR was largely increased after the oral glucose load, and the first phase of insulin secretion was restored after the IVGTT. The incretin response to OGTT was markedly enhanced.
The insulin sensitivity during the OGTT and the EHC was significantly improved after RYGB in both normotolerant and diabetic subjects; it increased, but not significantly, during the IVGTT. However, the indexes remained much smaller than those in healthy controls.
In diabetic subjects after RYGB, we found an inappropriately high insulin secretory response to the oral glucose load, which might explain the reported episodes of postprandial hypoglycemia, although the disposition index was not normalized. This is the first time that the ISR was measured in diabetic subjects after RYGB, although some relevant studies showed an increased plasma insulin concentration after the OGTT. 18 The large increase of the ISR after the oral glucose challenge might explain the remission of diabetes observed in our series. Interestingly, the ISR increased only when glucose was administered orally, whereas the intravenous route did not induce significant changes. A possible explanation of these findings is that the marked response of both GIP and GLP-1 to the oral glucose load might determine the increase of the ISR. In fact, the increase in the values of incretin data significantly correlates with the increase in the amplitude of the estimated ISR.
Laferrère et al 30 measured the incretin effect in response to an OGTT and to an isoglycemic intravenous glucose test in subjects with morbid obesity and type 2 diabetes. In accordance with our results, they found a remarkable increase in both total and active GLP-1 and GIP release in response to oral glucose, which preceded a large peak of circulating insulin 1 month after RYGB. The same team 31 showed that the increased incretin effect was associated with an increased early-phase and a decreased late-phase insulin and C-peptide peaks in response to the oral glucose challenge. These data agree with the evidence that GLP-1 infusion restores the early phase of insulin secretion. 32 In our series, the first phase of insulin secretion, which is usually very much reduced or absent in diabetic subjects, was restored in the IVGTT. Similar findings were observed after mainly malabsorptive bariatric surgery. 33 The insulin sensitivity was improved in both normotolerant and diabetic subjects independently of the route of glucose administration. However, the improvement resulted in values far different than the values found in healthy controls. Indeed, we have already shown in normoglycemic subjects that RYGB allowed a small improvement in the insulin sensitivity that was proportional to the weight loss. 34 Recently, Lima et al 35 showed that insulin sensitivity measured by the EHC did not increase significantly within a month after RYGB among premenopausal women. It is likely that this discrepancy derives from the heterogeneity of the groups of 9 subjects who underwent RYGB in the study of Lima et al, 35 which included subjects with normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes.
We assessed hepatic insulin sensitivity by the surrogate index QUICKI 28 and found that it was significantly improved in normal glucose tolerance and diabetic patients. It is possible that this improvement of hepatic insulin resistance is related to the caloric restriction. In fact, it has been largely shown in the literature that caloric restriction 36, 37 and reduction of liver glycogen 38 induce an acute decrease in HOMA-IR, an index equivalent to QUICKI in that it uses fasting plasma glucose and insulin levels.
This study has some limitations, although none have an impact on our findings. The small number of subjects within the subgroups reduces the power of across-group comparisons and will require further study. Furthermore, we did not measure the hepatic glucose output by using stable isotope infusion during the clamp to directly evaluate the hepatic insulin resistance.
In conclusion, our study shows that diabetes remission shortly after RYGB is mainly a consequence of the enhanced insulin secretion probably due to an increased incretin response to the oral glucose load. The first phase of insulin secretion was restored after gastric bypass. Fasting glucose and insulin levels were reduced, suggesting a net improvement in the hepatic insulin resistance. All these findings were observed in the diabetic patients, whereas the effect of RYGB on insulin secretion and sensitivity was blunted in the normotolerant morbidly obese subjects. ACKNOWLEDGMENTS S.S., G.M., A.B., and F.R. contributed to conception and design of the study. G.M., F.R., and C.G. participated in the study coordination, enrollment, and medical oversight of participants and data collection. F.R. performed surgical operations and provided critical revisions. S.S., A.B., and E.P. analyzed the data through mathematical models and performed statistical analysis. S.S., G.M., and A.B. participated in the data interpretation and wrote the manuscript.
